The effects of STING agonists are being explored in various diseases, including melanoma, colorectal cancer, anti-vascular therapies, metastasis, pancreatic cancer, influenza, aging, breast cancer, cervical cancer, SARS-CoV-2, HIV, and Mycobacterium tuberculosis infections. Here, STING1 is linked to familial pancreatic carcinoma.